Vistagen Therapeutics VTGN
NASDAQ VTGN
$0.19 -0.01 (-5.00%)
At close: Nov 19, 2026 · 4:00 PM EST

Vistagen Therapeutics (VTGN) Current Deferred Revenue (2011 - 2026)

Updated

Vistagen Therapeutics' Current Deferred Revenue was $96,000 in fiscal Q2 2027 (quarter ended Sep 30, 2026), down 95.5% from $2.14 million a year earlier and down 59.0% from the prior quarter.

Analysis

Vistagen Therapeutics (VTGN) Current Deferred Revenue (2011 - 2026) Analysis & Trends

At the end of FY2026 (ended Mar 31, 2026), Current Deferred Revenue at Vistagen Therapeutics came in at $1.71 million, down 33.9% from FY2025.

  • Current Deferred Revenue shows a five-year compound annual growth rate of 3.8% (FY2021 to FY2026).
  • In earlier fiscal years, Current Deferred Revenue was $2.59 million in FY2025 (+227.2%), $791,000 in FY2024 (+10.8%), $714,000 in FY2023 (-42.6%) and $1.24 million in FY2022 (-12.4%).
  • The fiscal Q2 2027 figure marks the lowest quarterly Current Deferred Revenue since fiscal Q4 2012.
  • Compared with a year earlier, Current Deferred Revenue has declined for five straight quarters, with growth averaging 3.2% over the last eight quarters.
  • The best year-over-year quarter for Current Deferred Revenue over five years was fiscal Q4 2025 (growth of 227.2%); the worst was fiscal Q2 2027 (a decline of 95.5%).
  • Per Business Quant data, VTGN's Current Deferred Revenue in the three fiscal quarters before Q2 2027 was $234,000 (Q1 2027), $1.71 million (Q4 2026) and $2 million (Q3 2026).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 PetVivo Holdings 3,096.39 Bn 3,096.39 Bn 196,075.00
2 Eli Lilly 1,202.70 Bn 1,176.32 Bn 20.46 Bn
3 Johnson & Johnson 649.77 Bn 569.63 Bn 17.30 Bn
4 AbbVie 507.00 Bn 475.00 Bn 13.12 Bn
5 Merck 329.70 Bn 292.64 Bn 13.19 Bn
6 Novartis Ag 291.91 Bn 265.14 Bn -
7 Amgen 236.26 Bn 187.91 Bn 7.58 Bn
8 Gilead Sciences 207.15 Bn 182.26 Bn 6.73 Bn
9 Gsk 193.54 Bn 176.38 Bn -
10 Vistagen Therapeutics 7.34 Mn -151.60 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 96,000.00
Jun 30, 2026 234,000.00
Mar 31, 2026 1.71 Mn
Dec 31, 2025 2.00 Mn
Sep 30, 2025 2.14 Mn
Jun 30, 2025 2.51 Mn
Mar 31, 2025 2.59 Mn
Dec 31, 2024 2.51 Mn
Sep 30, 2024 2.47 Mn
Jun 30, 2024 2.30 Mn
Mar 31, 2024 791,000.00
Dec 31, 2023 1.76 Mn
Sep 30, 2023 793,000.00
Jun 30, 2023 714,300.00
Mar 31, 2023 714,000.00
Dec 31, 2022 712,300.00
Sep 30, 2022 712,300.00
Jun 30, 2022 1.24 Mn
Mar 31, 2022 1.24 Mn
Dec 31, 2021 1.42 Mn
API Access

Vistagen Therapeutics Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=VTGN&period=max&api_key=YOUR_API_KEY